The development of de novo psoriasis in patients treated with tumor necrosis factor-alpha antagonists is well recognized. The authors hereby report a case of palmplantar pustular psoriasis in a patient with rheumatoid arthritis treated with etanercept. The condition responded to topical steroids but re-occurred upon treating the patient with certolizumab pegol. This strongly suggests that the development of de novo psoriasis is a class effect.
|Original language||English (US)|
|Number of pages||2|
|Journal||Journal of Clinical and Aesthetic Dermatology|
|State||Published - Aug 1 2012|
ASJC Scopus subject areas